B8FK Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Biofrontera (ETR: B8FK)
›
Biofrontera (ETR: B8FK) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 54 employees.
The shares were at 2.810 EUR on 19 November 2026, up 10.2% over 52 weeks. Its 52-week range is 2.220 EUR to 3.700 EUR: the price is 24.1% below the high and 26.6% above the low.
Its market capitalisation is 17.08M EUR.
Biofrontera reports return on equity of -26.6%, an operating margin of 11.3% and revenue up 78.2% year over year.
It holds more cash than debt, a net cash position of 5.48M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.